Sabatini Brent reported grant involving 50,000 shares of Vir Biotechnology, Inc. at $0.00 for $0 on Nov 15, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
SVP, Chief Accounting Officer
SVP, Chief Accounting Officer
Filed Nov 16, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
50,000Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
111,902Direct
Trade date
Nov 15, 2026Grant
Filed
Nov 16, 2026, 12:15 PM ET1-day reporting delay
Accession
0001628280-26-074055Code A · Transaction 401738
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

VIR price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VIR · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 23, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −17%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: 25% of the RSUs will vest on November 15, 2027, and the remaining RSUs will vest in three equal annual installments thereafter.